Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall \r\n- Vaccine 100% effective against severe or critical symptomatic COVID-19 \r\n- No safety concerns reported
Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of \u00a34.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children\u2019s and young people\u2019s cancers, with the hope of finding new ways to prevent and treat these complex cancers.
Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
A preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
![](\"https://www.paediatrics.ox.ac.uk/news/oxford-vaccine-professor-rich-countries-have-a-moral-duty-to-share-their-covid-19-shots/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n